Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma
Sci Transl Med. 2022 Apr 20;14(641):eabl8146. doi: 10.1126/scitranslmed.abl8146. Epub 2022 Apr 20.ABSTRACTAsthma and inflammatory airway diseases restrict airflow in the lung, compromising gas exchange and lung function. Inhaled corticosteroids (ICSs) can reduce inflammation, control symptoms, and improve lung function; however, a growing number of patients with severe asthma do not benefit from ICS. Using bronchial airway epithelial brushings from patients with severe asthma or primary human cells, we delineated a corticosteroid-driven fibroblast growth factor (FGF)-dependent inflammatory axis, with FGF-responsive fibrobl...
Source: Cancer Control - April 20, 2022 Category: Cancer & Oncology Authors: Riccardo Guidi Daqi Xu David F Choy Thirumalai R Ramalingam Wyne P Lee Zora Modrusan Yuxin Liang Scot Marsters Avi Ashkenazi Alison Huynh Jessica Mills Sean Flanagan Shannon Hambro Victor Nunez Laurie Leong Ashley Cook Tiffany Hao Tran Cary D Austin Yi Ca Source Type: research
Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study
Conclusions
Patients undergoing treatment with FP/FORM and FF/VI versus FP/SAL, BDP/FORM and BUD/FORM were associated with greater treatment adherence (persistence, MPR) and lower rates of exacerbations. However, further studies will be needed to strengthen the consistency of the results. (Source: BMJ Open)
Source: BMJ Open - April 20, 2022 Category: General Medicine Authors: Sicras-Mainar, A., Gomez Rodriguez, B., Traseira-Lugilde, S., Fernandez-Sanchez, T., Velasco Garrido, J. L. Tags: Open access, General practice / Family practice Source Type: research
Chronic Allergen Challenge Induces Corticosteroid Insensitivity With Persistent Airway Remodeling and Type 2 Inflammation
Type 2-high severe asthma is described as a distinct endotype with Th2 inflammation, high eosinophil lung infiltration, impaired lung function, and reduced corticosteroid sensitivity. While the inflammatory milieu is similar to mild asthma, patients with type 2-high severe asthma likely have underlying mechanisms that sustain asthma pathophysiology despite corticosteroid treatments. Acute and chronic allergen models induce robust type 2 inflammatory responses, however differences in corticosteroid sensitivity remains poorly understood. In the present study, we sensitized and challenged mice with ovalbumin (OVA; acute model...
Source: Frontiers in Pharmacology - April 11, 2022 Category: Drugs & Pharmacology Source Type: research
Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
The increasing use of technological devices for the management of diabetes is related to the prolonged exposure of patients’ skin to chemical and mechanical agents and, consequently, to the increased risk of developing dermatological complications. Among these, contact dermatitis is the most insidious skin disorder. Despite the magnitude of the issue, no universally accepted recommendations on the management of this common complication are currently available. Our observational study aimed to describe all the solutions adopted by patients and their caregivers to treat and prevent the appearance of contact dermatitis and ...
Source: Frontiers in Endocrinology - March 15, 2022 Category: Endocrinology Source Type: research
New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management
This article reviews efficacy versus systemic activity profiles for various dosing regimens of budesonide (BUD) and fluticasone propionate (FP). We performed a structured literature review of BUD and FP regular daily dosing, and BUD/formoterol (FOR) as-needed dosing, to explore the relationship between various dosing patterns of ICS regimens and the risk –benefit profile in terms of the extent of bronchoprotection and cortisol suppression. In addition, we explored how adherence could potentially affect the risk–benefit profile, in patients with mild, moderate, and moderate-to-severe asthma. With a specific focus on BUD...
Source: Advances in Therapy - March 14, 2022 Category: Drugs & Pharmacology Source Type: research
